Ovarian Cancer Clinical Trial
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Summary
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.
Eligibility Criteria
This study only enrolled participants who took part in previous studies of vismodegib conducted by Genentech.
Inclusion Criteria:
Completed vismodegib treatment within 2-4 weeks in a Genentech-sponsored parent study or continued to receive vismodegib at the time the Genentech-sponsored parent study closed.
Expectation by the investigator that the participant may continue to benefit from additional vismodegib treatment.
Exclusion Criteria:
Intervening anti-tumor therapy not specified in the parent study (ie, non-protocol-specified chemotherapy, other targeted therapy, radiation therapy, or photodynamic therapy).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 10 Locations for this study
Scottsdale Arizona, 85258, United States
Oakland California, 94609, United States
Palm Springs California, 92262, United States
Stanford California, 94305, United States
Baltimore Maryland, 21231, United States
Ann Arbor Michigan, 48109, United States
Detroit Michigan, 48201, United States
Las Vegas Nevada, 89106, United States
Cincinnati Ohio, 45242, United States
Houston Texas, 77030, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.